KYORIN Pharmaceutical Co., Ltd.
Q1 Earnings Report (Consolidated) for Fiscal Year Ending March 2027
In the first quarter of fiscal year ending March 2027, Kyorin Pharmaceutical reported net sales of approximately ¥296.5 billion, operating income of approximately ¥96.4 billion, and net income of approximately ¥82.4 billion, achieving increases compared to the same period last year.
Key Figures
- Net Sales: ¥29,654 million (YoY +1.9％)
- Operating Income: ¥964 million (YoY +59.3％)
- Net Income: ¥824 million (YoY +60.8％)
AI要約
Performance Overview
In the first quarter of fiscal year ending March 2027, Kyorin Pharmaceutical recorded net sales of ¥29,654 million (YoY +1.9%), operating income of ¥964 million (YoY +59.3%), and net income of ¥824 million (YoY +60.8%), achieving growth in both sales and profit. Domestic and international pharmaceutical sales remained robust, with significant improvements driven by new drug launches and cost management efforts. Overseas business also performed well, with increased overseas sales.
Future Outlook and Impact on Investors
The company aims to continue expanding sales and profits through the launch of new drugs and promotion of existing products. Emphasis will be placed on overseas expansion and the introduction of new pharmaceuticals to drive long-term growth. For investors, improved profit margins and a stable growth outlook make the company an attractive investment, with expectations for share price appreciation.
Net Sales Trend
Operating Income Trend
Net Income Trend
Profit Margin Composition
Kyorin Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
